To include your compound in the COVID-19 Resource Center, submit it here.

Not so fast

Two investors argue that Icagen is selling itself short in Pfizer deal

Not so fast

Merlin Nexus LP and New Leaf Ventures think the 150% premium that Pfizer Inc. (NYSE:PFE) has offered to pay for Icagen Inc. (NASDAQ:ICGN) "dramatically undervalues"

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE